Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

Inclusion Criteria: 1. Ages 0-18 years, any sex 2. Histologically confirmed or clinically highly suspected neuroblastoma with planned imaging assessment 3. At least one measurable lesion on conventional imaging such as CT or MRI 4. ECOG performance status 0-2 and an expected survival of ≥3 months 5. Hematologic, hepatic, and renal function meeting the following criteria: Hb ≥ 90 g/L, ANC ≥ 1.5 × 10⁹/L, platelets ≥ 100 × 10⁹/L, ALT/AST ≤ 2.5 × ULN, Cr ≤ 1.5 × ULN 6. Informed consent signed by the subject or legal guardian Exclusion Criteria: 1. Known history of severe allergy to the radioactive isotope or molecular probe components to be used; 2. Pregnancy or lactation; 3. Receipt of high-dose chemotherapy/radiotherapy, radionuclide therapy, or participation in other interventional clinical trials within the past 4 weeks; 4. Severe or uncontrolled cardiac, pulmonary, hepatic, or renal insufficiency, or active severe infection; 5. Bone marrow suppression not yet recovered (Hb \< 90 g/L, ANC \< 1.5 × 10⁹/L, platelets \< 100 × 10⁹/L); 6. Inability to complete imaging examinations such as PET/CT (e.g., severe claustrophobia, inability to lie supine for ≥ 30 min); 7. Any other situation deemed inappropriate for enrollment by the investigator.